Amphastar Pharmaceuticals (AMPH) Non-Current Debt (2013 - 2026)

Amphastar Pharmaceuticals has reported Non-Current Debt for 14 years, with the latest figure at $609.6 million in Q2 2026.

• On a quarterly basis, Non-Current Debt changed 0.3% year-over-year to $609.6 million in Q2 2026; TTM through Jun 2026 was $609.6 million, a 0.3% change from a year earlier, with the FY2025 full-year figure at $608.7 million, up 1.18% from the prior year.
• Non-Current Debt was $609.6 million for Q2 2026 at Amphastar Pharmaceuticals, roughly flat from $609.8 million in the prior quarter.
• The five-year high for Non-Current Debt was $638.2 million in Q3 2023, with the low at $72.8 million in Q4 2022.
• Average Non-Current Debt over 5 years is $450.6 million, with a median of $595.2 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Non-Current Debt soared 762.31% in 2023, then fell 6.54% in 2024.
• Over 5 years, Non-Current Debt stood at $72.8 million in 2022, then soared by 709.43% to $589.6 million in 2023, then climbed by 2.04% to $601.6 million in 2024, then climbed by 1.18% to $608.7 million in 2025, then climbed by 0.13% to $609.6 million in 2026.
• The last three Non-Current Debt figures came in at $609.6 million (Q2 2026), $609.8 million (Q1 2026), and $608.7 million (Q4 2025), per Business Quant data.